IP Library Granted Patent US 9,168,295
Granted Patent B2
US 9,168,295 · App. 13/973,117 · Granted Oct 27, 2015

Vaccine peptide combinations

Inventors: Roderick Peter Hafner (Oxford, GB); Mark Larche (Hamilton, CA); Anthony Barrington Kay (London, GB)
Assignee: Circassia Limited
A61K39/35C07K7/08G01N33/56977A61K2039/53
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,168,295
App. No.
13/973,117
Granted
Oct 27, 2015
Kind
B2
Abstract

The present invention relates to compositions comprising peptides for preventing or treating allergy to cats, and in particular to optimal combinations of peptides.

Claims (14)

1. A pharmaceutical formulation comprising a pharmaceutically acceptable carrier or diluent, a preservative, and, as the only therapeutic ingredients:

the polypeptide which consists of the sequence of SEQ ID NO: 1;

the polypeptide which consists of the sequence of SEQ ID NO: 2;

the polypeptide which consists of the sequence of SEQ ID NO: 3;

the polypeptide which consists of the sequence of SEQ ID NO: 4;

the polypeptide which consists of the sequence of SEQ ID NO: 5;

the polypeptide which consists of the sequence of SEQ ID NO: 6; and

the polypeptide which consists of the sequence of SEQ ID NO: 7,

wherein each said polypeptide is present in an amount of 100 ng to 2 mg.

2. The formulation according to claim 1 , which comprises no further peptides.

3. The formulation according to claim 1 wherein each polypeptide as defined in claim 1 has a concentration in the range of 0.03 to 200 nmol/ml, 0.3 to 200 nmol/ml or 10 to 50 nmol/ml.

4. The formulation according to claim 1 , which is provided as an injectable solution, suspension or emulsion.

5. The formulation according to claim 1 , which is formulated for administration parenterally, subcutaneously, intradermally or transdermally.

6. The formulation according to claim 1 , which is provided in dry form for reconstitution.

Assignments (3)
CHANGE OF NAME Recorded Feb 15, 2023
From: ADIGA LIFE SCIENCES LIMITED
To: VAXERNA LIMITED
Reel/Frame 062706/0166 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2023
From: CIRCASSIA LIMITED
To: ADIGA LIFE SCIENCES LIMITED
Reel/Frame 062664/0140 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2013
From: HAFNER, RODERICK PETER; LARCHE, MARK; KAY, ANTHONY BARRINGTON
To: CIRCASSIA LIMITED
Reel/Frame 031268/0793 →
Priority Claims (1)
GB 0710529.9 · Jun 1, 2007 · national
Continuity (2)
Division 12602313
Related Publication 20140050750A1 · Feb 20, 2014